A Randomized, Double-Blind, Multi-Center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Phase of Trial: Phase III
Latest Information Update: 05 Nov 2015
At a glance
- Drugs Everolimus (Primary)
- Indications Gastric cancer
- Focus Registrational; Therapeutic Use
- Acronyms GRANITE-1
- Sponsors Novartis Pharmaceuticals
- 05 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Nov 2013 Planned end date changed from 1 Dec 2012 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 16 Sep 2013 Results published in the Journal of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History